Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project

被引:15
|
作者
de Wilde, Arno [1 ]
Ossenkoppele, Rik [1 ,2 ,3 ]
Pelkmans, Wiesje [1 ]
Bouwman, Femke [1 ]
Groot, Colin [1 ,2 ]
van Maurik, Ingrid [1 ]
Zwan, Marissa [1 ]
Yaqub, Maqsood [2 ]
Barkhof, Frederik [2 ,4 ,5 ]
Lammertsma, Adriaan A. [2 ]
Biessels, Geert Jan [6 ]
Scheltens, Philip [1 ]
van Berckel, Bart N. [1 ,2 ]
van der Flier, Wiesje M. [1 ,7 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam UMC, Alzheimer Ctr, Dept Neurol,Amsterdam Neurosci, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Neurosci, Dept Radiol & Nucl Med, Amsterdam, Netherlands
[3] Lund Univ, Clin Memory Res Unit, Malmo, Sweden
[4] UCL, Inst Neurol, London, England
[5] UCL, Inst Healthcare Engn, London, England
[6] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands
[7] Vrije Univ Amsterdam, Amsterdam Neurosci, Dept Epidemiol & Biostat, Amsterdam, Netherlands
关键词
Alzheimer's disease; Amyloid; Positron emission tomography; Appropriate use criteria; Dementia; Clinical practice; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS ASSOCIATION WORKGROUPS; NATIONAL INSTITUTE; DIAGNOSTIC GUIDELINES; TASK-FORCE; DISEASE; RECOMMENDATIONS; BIOMARKERS; DEMENTIA; MANAGEMENT;
D O I
10.1016/j.jalz.2019.07.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post-positron emission tomography diagnosis and management change between "AUC-consistent" and "AUC-inconsistent" patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post-positron emission tomography diagnosis (28%-21%) and management (32%-17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not. (C) 2019 The Authors. Published by Elsevier Inc.
引用
收藏
页码:1458 / 1467
页数:10
相关论文
共 50 条
  • [21] The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
    Amft, Michaela
    Ortner, Marion
    Eichenlaub, Udo
    Goldhardt, Oliver
    Diehl-Schmid, Janine
    Hedderich, Dennis M.
    Yakushev, Igor
    Grimmer, Timo
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [22] Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic
    Vives-Rodriguez, Ana Laura
    Schiloski, Kylie A.
    Marin, Anna
    Wang, Ryan
    Hajos, Gabor P.
    Powsner, Rachel
    DeCaro, Renee
    Budson, Andrew E.
    Turk, Katherine W.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2022, 8 (01)
  • [23] Combining neuropsychological assessment and structural neuroimaging to identify early Alzheimer's disease in a memory clinic cohort
    Quek, Yi-En
    Fung, Yi Leng
    Bourgeat, Pierrick
    Vogrin, Simon J.
    Collins, Steven J.
    Bowden, Stephen C.
    BRAIN AND BEHAVIOR, 2024, 14 (05):
  • [24] Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging
    Mustafa, Rafid
    Brosch, Jared R.
    Rabinovici, Gil D.
    Dickerson, Bradford C.
    Carrillo, Maria C.
    Glazier, Bradley S.
    Gao, Sujuan
    Tierney, Martha
    Fargo, Keith N.
    Austrom, Mary G.
    De Santi, Susan
    Clark, David G.
    Apostolova, Liana G.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2018, 32 (01) : 35 - 42
  • [25] Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria
    Maria Trivino-Ibanez, Eva
    Sanchez-Vano, Raquel
    Sopena-Novales, Pablo
    Carlos Romero-Fabrega, Juan
    Rodriguez-Fernandez, Antonio
    Carnero Pardo, Cristobal
    Martinez Lozano, Maria Dolores
    Gomez-Rio, Manuel
    MEDICINE, 2019, 98 (29) : e16509
  • [26] A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting
    Van Maurik, Ingrid S. S.
    Broulikova, Hana M. M.
    Mank, Arenda
    Bakker, Els D. D.
    De Wilde, Arno
    Bouwman, Femke H. H.
    Stephens, Andrew W. W.
    Van Berckel, Bart N. M.
    Scheltens, Philip
    Van Dser Flier, Wiesje M. M.
    ALZHEIMERS & DEMENTIA, 2023, 19 (05) : 2006 - 2013
  • [27] Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias
    Bao, Yi-Wen
    Chau, Anson C. M.
    Chiu, Patrick Ka-Chun
    Shea, Yat Fung
    Kwan, Joseph S. K.
    Chan, Felix Hon Wai
    Mak, Henry Ka-Fung
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 79 (02) : 819 - 832
  • [28] Identifying an Optimal Cutoff of the Montreal Cognitive Assessment to Predict Amyloid-PET Positivity in a Referral Memory Clinic
    Nair, Anil K.
    Ramaswamy, Srinath
    Kan, Krystal
    Nair, Shreya
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2019, 33 (03) : 194 - 199
  • [29] Brain amyloid PET interpretation approaches: from visual assessment in the clinic to quantitative pharmacokinetic modeling
    Chen, Yin Jie
    Nasrallah, Ilya M.
    CLINICAL AND TRANSLATIONAL IMAGING, 2017, 5 (06) : 561 - 573
  • [30] Utility of amyloid PET Imaging in a Memory Clinic
    Pletnikova, Alexandra
    Okhravi, Hamid R.
    Jamil, Nimra
    Kirby, Mackenzie
    Lyketsos, Constantine G.
    Oh, Esther S.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2023, 37 (04) : 270 - 273